Last reviewed · How we verify

NCT07172165: MESOMEGA

A Multicenter Study to Optimize Microembolic Signal Classification Based on Double--Blind Multiparametric Assessment by Human Experts Using an Universal Graphical Interface [MESOMEGA]

ENROLLING BY INVITATION Last updated 10 December 2025
What this trial tests

trial testing Expert double-blind evaluation in Microemboli in 850 participants. Enrolling by invitation.

Timeline
15 May 2025
Primary endpoint
15 December 2025
15 March 2026

Quick facts

Lead sponsorUniversidade do Porto
StatusENROLLING BY INVITATION
Study typeOBSERVATIONAL
Enrollment850
Start date15 May 2025
Primary completion15 December 2025
Estimated completion15 March 2026
Sites1 location across Portugal

Drugs / interventions tested

Conditions studied

Sponsor

Universidade do Porto — full company profile →

Who can join

18 and older, any sex, with Microemboli or Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Microembolic signals (MES) is a powerful predictor of future embolic events. This study aims to develop and validate a accurate model of classification of MES obtained by transcranial Doppler. monitoring of However, MES detection is technically demanding and requires expert interpretation. By providing a reproducible framework for MES interpretation, this work aims to facilitate MES integration into future clinical trials and decision-making.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Universidade do Porto trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07172165.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing